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A multiple sleep latency test (MSLT) with occurrence of sleep onset REM periods (SOREMP) is 
considered one of the central diagnostic criteria for narcolepsy according to the International 
Classification of Sleep Disorders, but its sensitivity and specificity have been questioned. This study 
aims to describe MSLT and polysomnography (PSG) findings, including frequency and distribution of 
SOREMP during the day, in a large cohort of patients with central disorders of hypersomnolence 
(CDH).  
We retrospectively analyzed electrophysiological data from MSLT and PSG in 370 consecutive 
patients with narcolepsy type 1 (NT1, n = 97), type 2 (NT2, n = 31), idiopathic hypersomnia (IH, n = 
48), nonorganic hypersomnia (NOH, n = 116) and insufficient sleep syndrome (ISS, n = 78).  
NT1 and NT2 patients had a significantly shorter mean Sleep Latency (mSL) and REM-Latency (REML) 
in MSLT and PSG. SOREMP occurred more frequently in narcoleptic vs. non-narcoleptic patients in 
MSLT and PSG. Occurrence of 3 or more SOREMP in MSLT and a SOREMP in PSG had a very high 
specificity and positive predictive value (98%/96% and 100% respectively), however relatively low 
sensitivity (65% and 45% respectively). 
NT1 more than NT2 patients have shorter mSL and more frequent SOREMP in MSLT and shorter SL as 
well as REML during nocturnal PSG. Increasing numbers of SOREMP in MSLT and especially SOREMP 
during PSG increase specificity on the expense of sensitivity in diagnosing narcolepsy. Therefore, 
frequency of SOREMP in MSLT naps and PSG can help to discriminate but not clearly separate 
narcoleptic from non-narcoleptic patients. 
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Excessive daytime sleepiness (EDS) was reported by up to 28% of the general adult US population in a 
study by Ohayon et al., but the prevalence depends on the exact definition [1]. According to the 
International Classification of Sleep Disorders (ICSD-3), EDS for at least 3 months is the main feature 
of central disorders of hypersomnolence (CDH) [2]. EDS is often underrated by patients, leading to 
underdiagnosis and undertreatment of sleep-wake disorders [3]. Subjective sleepiness is usually 
measured by the Epworth Sleepiness Scale (ESS)[4], a simple self-administered questionnaire, 
whereas the multiple sleep latency test (MSLT) is the most often used objective method [5]. 
The occurrence of ≥ 2 sleep onset REM periods (SOREMP) during the MSLT including the nocturnal 
Polysomnography (PSG) is an essential criterion for the diagnosis of narcolepsy type 1 (NT1) as well 
as narcolepsy type 2 (NT2) according to the ICSD-3 criteria [2]. However, the sensitivity and 
specificity of SOREMP for narcolepsy have been questioned over the last few years, since several 
studies demonstrated the presence of ≥ 2 SOREMP in a series of other diseases. In a cohort of 
healthy adults multiple SOREMP were detected in 13% of males and 6% of females; some of these 
healthy subjects even had a mSL of ≤ 8 min formally fulfilling electrophysiological criteria for NT1 or 
NT2 [6]. Seneviratne et al. found that up to 14% of patients with sleep-disordered breathing (SDB) 
had 2 or more SOREMP in the MSLT with a mean sleep latency (mSL) of 4.5 min in a clinically sleepy 
patient group [7]. Marti et al. found that 15% of patients with behaviorally induced insufficient sleep 
syndrome (ISS) had an MSLT suggestive of narcolepsy (mSL ≤ 8 min and at least two SOREMP) [8]. In 
line with these findings Drakatos et al. found 1 SOREMP in the MSLT of IH (1%), ISS (7.14%) and 
periodic limb movement disorder (4.7%) patients [9]. However, in the same study sleep stage 
sequence analysis discovered, that SOREMP arising from stage N1 has a high sensitivity for NT1 
diagnosis, since IH, ISS, PLMD and NT2 patients had mostly SOREMP arising from stage N2 [9]. The 
same study demonstrated that only narcoleptic patients present with SOREMP in the fourth 
(afternoon) nap of MSLT [9]. Occurrence of SOREMP during nocturnal PSG has been found highly 
specific for NT1 [10]. 
The aim of our present study was to test the current hypothesis of a specific temporal distribution 
pattern of SOREMP in MSLT and PSG in a large cohort of CDH patients comparing five diagnostic 
groups, including nonorganic hypersomnia patients. 
 








The current study was approved by the local ethical committee (Kantonale Ethikkommission Bern, 
2016-00409). For this study, we used data from a clinical registry from the Sleep-Wake-Epilepsy 
Center of the Department of Neurology at the Inselspital in Bern, initiated in 1997. Clinical and 
electrophysiological data from each consecutive patient consultation, that included 
electrophysiological examinations at the Sleep-Wake-Epilepsy-Center, Department of Neurology, 
University Hospital Bern, Inselspital, were entered into the database manually.  
For the present study, all data sets from 2001 until 2016 were extracted from the original clinical 
registry and transferred to a Research Electronic Data Capture ( REDCap®) database containing only 
coded clinical and electrophysiological data. Study data were collected and managed using REDCap® 
electronic data capture tools hosted at the department of Neurology, University Hospital and 
University of Bern, Inselspital, Bern, Switzerland[11,12]. REDCap® is a secure, web-based software 
platform designed to support data capture for research studies, providing 1) an intuitive interface for 
validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) 
automated export procedures for seamless data downloads to common statistical packages; and 4) 
procedures for data integration and interoperability with external sources. 
Each original data set contained a final diagnosis (according to the third or second edition or earlier 
versions of the international classification of sleep disorders from the American Academy of Sleep 
Medicine (AASM)). After data transfer all records were reviewed and confirmed manually by two 
sleep specialists [2]. In cases of a documented change in diagnosis during a follow-up consultation 
(e.g., initially NT1 after electrophysiological workup, however changed to ISS after hypocretin 
measurement and due to clinical judgment during follow-up consultations), the final diagnosis was 
used for the analysis, irrespectively of the initial interpretation of diagnostic workup. The term 
nonorganic hypersomnia is used as an alternative name of hypersomnia associated with a psychiatric 
disorder in ICSD 3 and is also described in ICD-10 under the Code F51.1. Excessive daytime sleep or 
sleep attacks not accounted for by inadequate sleep and/or prolonged transition to the fully aroused 
state upon awakening (sleep drunkenness) are criteria for NOH under the ICD-10[13]. A description 
of NOH classification in our cohort has been published elsewhere[14]. 
Exclusion criteria included incomplete clinical information, incomplete sleep-wake test datasets, as 
well as the presence of other sleep comorbidities with a potential effect on sleep architecture or 
unclear CDH diagnosis. 
We analyzed electrophysiological data from PSG and MSLT, as well as HLA DQB1*0602 status and CSF 
hypocretin-1 concentration data, if available, from five selected diagnostic groups with CDH, namely 








(REML) from PSG and the individual mean sleep latency (mSL) and individual mean REM-latency 
(mREML) from MSLT were compared between groups by comparing their median values. Proportions 
of patients with SOREMP occurring on PSG or MSLT naps were compared between groups. However, 
for SOREMP analysis only descriptive statistics were used since groups were – as expected – very 
heterogeneous. If no REM appeared in a single MSLT or PSG trial, subjects were not considered for 
REM-Latency or SOREMP analysis. CSF hypocretin-1 levels <20 pg/mL were referred to as 
undetectable hypocretin-1, levels between 20 and 110 pg/mL were considered as low, whereas levels 
>110 were considered as normal.  
Statistical analyses and graphs were performed by Stata/MP 16.0. Data were described by medians 
(interquartile range (IQR). To compare continuous measures among the five groups, we used the 





We analyzed clinical and electrophysiological data of 370 consecutive patients with clear-cut CDH 
diagnoses from our center over 15 years (2001-2016). Patients not fulfilling diagnostic criteria or 
largely incomplete datasets were not included in the analysis. As summarized in table 1, 97 (26%) 
patients were diagnosed with NT1, 31 (8%) with NT2, 48 (13%) with IH, 116 (31%) with NOH, and 78 
(21%) with ISS. HLA DQB1*06:02 status and hypocretin measurements when available are given in 
table 1. 
Electrophysiological studies 
Overall, 349 patients underwent PSG and 313 MSLT. Overall, 292 (79%) patients underwent both PSG 
and MSLT, while 56 (15%) had only PSG. 77% patients completed 5 MSLT trials, 21% 4 trials and 2% 
less than 4 trials.  
Multiple Sleep Latency Test (MSLT) 
As shown in figure 1, the median mSL overall patients was 5.1 (Interquartile Range IQR 4.9 min, 
n=313), shortest for NT1 with 2.7 (IQR 2.4, n=84) min, NT2 with 4.0 (IQR 3.8, n=31) min, IH with 5.2 
(IQR 4.3, n=48) min, NOH with 7.4 (IQR 4.5, n=97) min and ISS with 5.3 (IQR 6, n=53) min. REM sleep 
in any MSLT round occurred in overall 133 (43%) patients, in 77 (92%) NT1, 29 (94%) NT2, 6 (12.5%) 








min, shortest for NT1 with 6.0 (IQR 5.4) min, NT2 with 7.1 (IQR 3.1) min, IH with 10.5 (IQR 2.5) min, 
NOH with 9.5 (IQR 7.8) min and ISS with 9.8 (IQR 5.8) min.  
As shown in table 2, SOREMP (as defined by REML <15min after sleep onset) occurred during any 
MSLT nap in 92% of NT1 patients, in 94% of NT2 patients, in 13% of IH patients, in 13% of NOH 
patients and in 15% of ISS patients (p < 0.0001, table 2). Up to three or more SOREMP in the course 
of 5 MSLT naps occurred in 75% of NT1 patients and only 39% of NT2, 2% of NOH or ISS patients and 
none of the IH patients (table 2). 
Polysomnography (PSG) 
As shown in figure 1 the median SL overall patients was 6 (IQR 9.5, n=349) min, shortest for NT1 with 
3.1 (IQR 4, n= 93,) min compared to NT2 with 7.0 (IQR 9.5, n= 29) min, IH with 5.0 (IQR 5, n= 45) min, 
NOH with 11.0 (IQR 21, n=109) min and ISS with 5.5 (IQR 8, n=73) min. The median PSG REML was 
overall 91 (IQR 85) min, shortest for NT1 with 11.8 (IQR 87) min, NT2 with 70.5 (IQR 42.5) min, IH 
with 93.0 (IQR 75.5) min, NOH with 128.8 (IQR 96.25) min and ISS with 95.0 (IQR 68.5) min.  
SOREMP during PSG were found overall patients in 16% (n = 55), in 53% (n = 49) of NT1 patients, 21% 
(n = 6) of NT2 patients and no SOREMP was registered in IH, NOH or ISS patients (p<0.0001), as 
described in table 2. 
Sensitivity, specificity and positive predictive value of SOREMP 
As expected by definition, narcoleptic patients had significantly more MSLT and PSG SOREMP 
compared to non-narcoleptic patients (p < 0.001, table 3). Using ICSD3 criteria[2] of two or more 
SOREMP in either two of the MSLT naps or one SOREMP in PSG and at least one SOREMP in MSLT 
naps had a high sensitivity of 90% and specificity of 95% with a positive predictive value of 91% 
discriminating narcoleptic vs. non-narcoleptic patients. Testing criteria of SOREMP in 3 or more MSLT 
naps had a sensitivity of 65%, specificity of 98% and positive predictive value (PPV) of 96% in 
discriminating narcoleptic vs. non-narcoleptic patients. SOREMP in PSG had a lower sensitivity of 
45%, higher specificity of 100% and PPV of 100%. Combined, 3 or more SOREMP in MSLT and 
SOREMP in PSG had an even lower sensitivity of 38%, specificity and PPV of 100%.  
 
Discussion 
The present study investigated diagnostic parameters of MSLT and PSG in a large cohort of 370 CDH 








The main finding of our study is, as expected, significantly shorter mSL and REML in MSLT and PSG in 
NT1 compared to non-narcoleptic patients. Furthermore, distinguishing features for narcolepsy vs 
non-narcoleptic sleepy patients were up to three or more SOREMP in the course of the 5 MSLT naps 
(75% NT1 vs. 2% NOH, 2% ISS, 0% IH) and SOREMP in the PSG (53% NT1, 0% in IH, NOH, ISS). Applying 
AASM ICSD3 criteria[2] of 2 or more SOREMP in MSLT (including PSG) had a high sensitivity (90%), 
specificity (95%) and positive predictive value (91%) discriminating narcoleptic vs. non-narcoleptic 
patients. These findings are however most probably strongly biased by “circular reasoning” in such a 
retrospective study design. Increasing the limit to 3 or more SOREMP resulted in a higher  specificity 
and positive predictive value (98%/96% and 100% respectively, however in a relatively low sensitivity 
(65% and 45% respectively) in discriminating narcoleptic vs. non-narcoleptic patients. A reliable 
differentiation between NT1 and NT2 with these parameter was however not possible, as expected, 
due to the similar electrophysiological diagnostic criteria [2].  
These findings are perfectly in line with literature: Aldrich et al. reported a sensitivity and specificity 
of 3 or more SOREMP in MSLT of 48% and 98%, and SOREMP in PSG of 29% and 98% [15]. Andlauer 
et al. reported a sensitivity and specificity of 51% and 99% for PSG SOREMP in patients with NT1 vs. 
population based controls [10].  
In a study by Drakatos et al. SOREMP occurred in NT1 patients in 63% of all MSLT naps, in NT2 in 
60%, in IH in only 1% and in ISS patients in 7% [9]. Furthermore, a relatively homogeneous temporal 
distribution of SOREMP occurrence during the course of an MSLT day was shown for NT1 and NT2 
[9]. In line with these results, we found proportions of narcolepsy, especially NT1 patients with 
SOREMP occurring in individual MSLT naps relatively evenly distributed throughout the course of the 
MSLT examination day (78% in MSLT nap 1 decreasing to 65% in MSLT nap 5). However, a statistical 
comparison of this temporal distribution to occurrence of SOREMP in non-narcoleptic groups was not 
rational, due to the very small total numbers of detected SOREMP in the non-narcoleptic groups. 
Therefore, the hypothesis of a narcolepsy specific pattern of temporal distribution of SOREMP in 
MSLT can neither be confirmed nor rejected, due to a too small non-narcoleptic control group 
experiencing SOREMP in MSLT.  
We found valuable MSLT and PSG criteria distinguishing narcoleptic from  non-narcoleptic CDH 
patients. However, none of the investigated parameter allowed to distinguish NT1 from NT2 and  the 
big overlap of all parameters such as sleep latency between the diagnostic groups in our cohort, 
supports literature criticism on the official electrophysiological gold standard criteria in diagnosing 
CDH patients[16]. Our data underline once again the importance of detailed history taking and 








concept of CDH with better clinical, electrophysiological or biological markers would be needed 
[17,18]. 
Multiple studies on PSG and MSLT characteristics of patients with EDS have been published so far. 
However, studies with very large cohorts of up to 2500 subjects[19–21] either describe overall 
population based results without going into detail of CDH diagnostic groups or are not especially 
focused on narcolepsy and narcolepsy related disorders. Other studies, comparing CDH patients and 
other sleepy patient groups, mostly have limited numbers of study population between 20 to 90 
patients per diagnostic group[8,9,22], often comparing only 2 to 3 CDH diagnostic groups. Studies on 
NOH patients are rare[14]. Therefore, the main strength of this study is the relatively large number of 
included patients with mostly full data sets on PSG and MSLT data, including NOH patients. The 
major limitations of this study are the retrospective study design, and the lack of interpretation of 
other available data such as subjective measures of sleepiness (e.g. Epworth Sleepiness Scale), 
disease onset, treatment status and the lack of follow up data. 
Conclusion 
In conclusion, NT1 more than NT2 patients have shorter mSL and more frequent SOREMP in MSLT 
and shorter SL as well as REML during nocturnal PSG. The more SOREMP occur in MSLT and PSG the 
higher is the probability of discriminating narcoleptic from non-narcoleptic CDH patients, but 
increasing this limit resulting in greater specificity is at the expense of lower sensitivity. SOREMP 
occurred evenly distributed throughout a day of 5 MSLT naps in narcolepsy, including the PSG, 
especially in NT1 patients. Therefore, frequency and temporal distribution of SOREMP in MSLT naps 
and PSG can help to discriminate but not clearly separate narcoleptic from non-narcoleptic patients. 
It remains essentially important to carefully phenotype patients clinically as well as 
electrophysiologically, besides research approaches to find novel biomarkers as well as investigation 
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Table legend: NT1 narcolepsy type 1, NT2 narcolespy type 2, IH idiopathic hypersomnia, NOH nonorganic hypersomnia, ISS insufficient sleep syndrome, IQR 
interquartile range.  
  
 
NT1 NT2 IH NOH ISS 
n 97 31 48 116 78 
Male/female 61/36 22/9 15/33 43/73 45/33 
Median Age in years (IQR) 36 (27) 32 (20) 24 (8.5) 38 (22) 28 (22) 
HLA DQB1*06:02 
positive/available 
66/67 15/28 3/24 n.d. n.d. 
Hypocretin measured 18 7 n.d. n.d. n.d. 
Median Hypocretin (range) 
pg/ml 








Table 2 Proportions of patients with SOREMP in MSLT and PSG 
 NT1 NT2 IH NOH ISS 
n patients with MSLT 84 31 48 97 53 
n patients with MSLT SOREMP 
any MSLT nap* 
77 (92, 84-96) 29 (94, 78-98) 6 (13, 6-25) 13 (13, 8-22) 8 (15, 8-28) 
MSLT nap 1** 78 (68-86) 65 (47-79) 9 (3-21) 9 (4-16) 4 (1-15) 
MSLT nap 2 66 (55-76) 52 (35-68) 2 (0-14) 5 (2-12) 2 (0-13) 
MSLT nap 3 66 (55-75) 43 (27-61) 0 3 (1-9) 4 (1-14) 
MSLT nap 4 63 (52-72) 61 (43-77) 4 (1-15) 3 (1-9) 8 (3-19) 
MSLT nap 5 65 (55-75) 17 (7-34) 0 4 (2-11) 4 (1-15) 
n (%) patients with number of MSLT SOREMP    
0 SOREMP 7 (8) 2 (7) 42 (88) 84 (87) 45 (85) 
1 SOREMP 6 (6) 3 (10) 5 (10) 6 (6) 6 (11) 
2 SOREMP 9 (11) 14 (45) 1 (2) 5 (5) 1 (2) 
3 SOREMP 18 (21) 7 (23) 0 (0) 2 (2) 1 (2) 
4 SOREMP 25 (30) 5 (16) 0 (0) 0 (0) 0 (0) 
5 SOREMP 20 (24) 0 (0) 0 (0) 0 (0) 0 (0) 
n patients PSG 93 29 45 110 74 
n patients with PSG SOREMP* 49 (53, 43-63) 6 (21, 10-39) 0 (0) 0 (0) 0 (0) 
Table legend: MSLT Multiple Sleep Latency Test, PSG Polysomnography, SOREMP Sleep Onset REM Period, NT1 narcolepsy type 1, NT2 narcolepsy type 2, IH 
idiopathic hypersomnia, NOH nonorganic hypersomnia, ISS insufficient sleep syndrome, *Data are n, % (95% CI), **Data are proportions of patients in % (95% 









Figure 1 Comparison of Sleep and REM Latency in MSLT and PSG between groups 
 
Figure legend: MSLT Multiple Sleep Latency Test, PSG Polysomnography, REM rapid eye movement, NT1 narcolepsy type 1, NT2 narcolepsy type 2, IH idiopathic 









NT1 NT2 IH NOH ISS







NT1 NT2 IH NOH ISS




































PPV (95% CI) 
≥ 2 SOREMP in MSLT 
and/or PSG° 
99/110 10/186 <0.0001 90% (83-95) 95% (90-97) 91% (84-95) 
≥ 3 SOREMP in MSLT 
and SOREMP in PSG 
42/110 0/186 <0.0001 38% (29-48) 100% (98-100) 100% 
≥ 3 SOREMP in MSLT 75/115 3/198 <0.0001 65% (56-74) 98% (96-100) 96% (89-98) 
SOREMP in PSG 55/122 0/229 <0.0001 45% (36-54) 100% (98-100) 100% 
Table legend: SOREMP Sleep Onset REM Period, MSLT Multiple Sleep Latency Test, PSG Polysomnography, PPV positive predictive value, *χ2 test, °according to 









Manuscript: Multiple Sleep Latency Test and Polysomnography in Patients with Central Disorders of 
Hypersomnolence 
 
• SOREMP, especially in PSG occur far more frequently in narcoleptic patients 
• However, also other sleepy CDH patients may have up to 3 SOREMP in MSLT/PSG 
• In NT patients SOREMP occur evenly distributed throughout a day of 5 MSLT naps 
• SOREMP help but not discriminate narcoleptic from non-narcoleptic sleepy patients 
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